{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:44:13Z","timestamp":1787319853102,"version":"build-2736575974"},"reference-count":123,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Korea Healthcare Technology R & D Project, Ministry of Health & Welfare","award":["A111949"],"award-info":[{"award-number":["A111949"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.pnpbp.2012.10.018","type":"journal-article","created":{"date-parts":[[2012,10,31]],"date-time":"2012-10-31T04:01:19Z","timestamp":1351656079000},"page":"207-213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"special_numbering":"C","title":["Oxidative stress and tardive dyskinesia: Pharmacogenetic evidence"],"prefix":"10.1016","volume":"46","author":[{"given":"Chul-Hyun","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heon-Jeong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2012.10.018_bb0005","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2165\/00129785-200505030-00002","article-title":"Genetics and epigenetics in major psychiatric disorders: dilemmas, achievements, applications, and future scope","volume":"5","author":"Abdolmaleky","year":"2005","journal-title":"Am J Pharmacogenomics"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0010","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1034\/j.1600-079X.2001.300201.x","article-title":"Melatonin, mitochondria, and cellular bioenergetics","volume":"30","author":"Acuna-Castroviejo","year":"2001","journal-title":"J Pineal Res"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0015","first-page":"421","article-title":"Effects of calcium-channel antagonists on tardive dyskinesia and psychosis","volume":"24","author":"Adler","year":"1988","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0025","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1176\/ajp.150.9.1405","article-title":"Vitamin E treatment of tardive dyskinesia","volume":"150","author":"Adler","year":"1993","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0020","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/S0006-3223(97)00027-9","article-title":"Long-term treatment effects of vitamin E for tardive dyskinesia","volume":"43","author":"Adler","year":"1998","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0030","first-page":"124","article-title":"Vitamin E in the treatment of tardive dyskinesia","volume":"39","author":"Akhtar","year":"1993","journal-title":"J Postgrad Med"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0035","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.pnpbp.2004.10.014","article-title":"Association between Ala\u20139Val polymorphism of Mn-SOD gene and schizophrenia","volume":"29","author":"Akyol","year":"2005","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0040","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/hup.1087","article-title":"Missense polymorphisms in three oxidative-stress enzymes (GSTP1, SOD2, and GPX1) and dyskinesias in Russian psychiatric inpatients from Siberia","volume":"25","author":"Al Hadithy","year":"2010","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0045","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0301-0082(99)00064-7","article-title":"Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia?","volume":"61","author":"Andreassen","year":"2000","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0050","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/ana.20296","article-title":"Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia","volume":"57","author":"Aubert","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0055","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/sj.mp.4002142","article-title":"Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions","volume":"13","author":"Bakker","year":"2008","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0060","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/sj.mp.4000847","article-title":"Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia","volume":"6","author":"Basile","year":"2001","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0065","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/ana.410380304","article-title":"Aging, energy, and oxidative stress in neurodegenerative diseases","volume":"38","author":"Beal","year":"1995","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.pnpbp.2012.10.018_bb0070","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/00001756-199512000-00085","article-title":"Haloperidol-induced cell death \u2014 mechanism and protection with vitamin E in vitro","volume":"7","author":"Behl","year":"1995","journal-title":"Neuroreport"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0075","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/0149-7634(94)90001-9","article-title":"Free radical mechanisms in schizophrenia and tardive dyskinesia","volume":"18","author":"Cadet","year":"1994","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0080","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1749-6632.1989.tb14918.x","article-title":"Possible involvement of free radicals in neuroleptic-induced movement disorders. Evidence from treatment of tardive dyskinesia with vitamin E","volume":"570","author":"Cadet","year":"1989","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0085","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/0006-3223(90)90461-A","article-title":"Chronic treatment with prolixin causes oxidative stress in rat brain","volume":"28","author":"Cadet","year":"1990","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0090","article-title":"Affective disorders and tardive dyskinesia","volume":"14","author":"Casey","year":"1988","journal-title":"Enc\u00e9phale"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0095","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1001\/archpsyc.1980.01780250062007","article-title":"gamma-Acetylenic GABA in tardive dyskinesia","volume":"37","author":"Casey","year":"1980","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0100","first-page":"252","article-title":"Effectiveness of melatonin in tardive dyskinesia","volume":"52","author":"Castro","year":"2011","journal-title":"Invest Clin"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0105","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0006-3223(96)00543-4","article-title":"Association of TaqI A polymorphism of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia","volume":"41","author":"Chen","year":"1997","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0110","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/ajmg.b.10004","article-title":"Polymorphisms of dopamine receptors and tardive dyskinesia among Chinese patients with schizophrenia","volume":"116B","author":"Chong","year":"2003","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0115","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/ana.410260518","article-title":"Deprenyl suppresses the oxidant stress associated with increased dopamine turnover","volume":"26","author":"Cohen","year":"1989","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0120","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/YCO.0b013e3282f53132","article-title":"Tardive dyskinesia and new antipsychotics","volume":"21","author":"Correll","year":"2008","journal-title":"Curr Opin Psychiatry"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0125","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1176\/ajp.151.6.925","article-title":"Effectiveness of vitamin E for treatment of long-term tardive dyskinesia","volume":"151","author":"Dabiri","year":"1994","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0130","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/01.jcp.0000177546.34799.af","article-title":"Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness","volume":"25","author":"de Leon","year":"2005","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0135","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/00004714-199010060-00006","article-title":"Nifedipine in the treatment of tardive dyskinesia","volume":"10","author":"Duncan","year":"1990","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0140","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1176\/ajp.149.6.773","article-title":"Treatment of tardive dyskinesia with vitamin E","volume":"149","author":"Egan","year":"1992","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0150","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1093\/oxfordjournals.schbul.a033414","article-title":"Tardive dyskinesia: possible involvement of free radicals and treatment with vitamin E","volume":"25","author":"Elkashef","year":"1999","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0145","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1176\/ajp.147.4.505","article-title":"Vitamin E in the treatment of tardive dyskinesia","volume":"147","author":"Elkashef","year":"1990","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0155","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/B978-0-12-381328-2.00004-3","article-title":"Molecular mechanisms of l-DOPA-induced dyskinesia","volume":"98","author":"Fisone","year":"2011","journal-title":"Int Rev Neurobiol"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0160","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1093\/nar\/gkh536","article-title":"Evidence that RNA editing modulates splice site selection in the 5-HT2C receptor gene","volume":"32","author":"Flomen","year":"2004","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0165","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1002\/pro.5560071225","article-title":"The trail to superoxide dismutase","volume":"7","author":"Fridovich","year":"1998","journal-title":"Protein Sci"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0170","first-page":"937","article-title":"Manganese superoxide dismutase gene (MnSOD) polymorphism in schizophrenics with tardive dyskinesia from central Poland","volume":"40","author":"Galecki","year":"2006","journal-title":"Psychiatr Pol"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0175","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s007020070089","article-title":"Haloperidol-induced neurotoxicity \u2014 possible implications for tardive dyskinesia","volume":"107","author":"Galili","year":"2000","journal-title":"J Neural Transm"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0180","doi-asserted-by":"crossref","first-page":"10S","DOI":"10.1097\/00004714-198808001-00003","article-title":"Predictors of occurrence, severity, and course of tardive dyskinesia in an outpatient population","volume":"8","author":"Glazer","year":"1988","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0185","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/0306-4530(83)90022-7","article-title":"The relationship of circulating estradiol to tardive dyskinesia in men and postmenopausal women","volume":"8","author":"Glazer","year":"1983","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0190","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0306-4530(85)90011-3","article-title":"Estrogen replacement and tardive dyskinesia","volume":"10","author":"Glazer","year":"1985","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0195","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/0006-3223(93)90119-X","article-title":"A placebo-controlled trial of selegiline (l-deprenyl) in the treatment of tardive dyskinesia","volume":"33","author":"Goff","year":"1993","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0200","first-page":"97","article-title":"Modulation of tardive dyskinesia by estrogen: neurochemical studies in an animal model","volume":"104","author":"Gordon","year":"1979","journal-title":"Trans Am Neurol Assoc"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0205","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1006\/abbi.2001.2630","article-title":"Reactive oxygen species and protein oxidation in aging: a look back, a look ahead","volume":"397","author":"Hensley","year":"2002","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0210","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.pnpbp.2006.12.019","article-title":"Association between the MnSOD Ala\u20139Val polymorphism and development of schizophrenia and abnormal involuntary movements in the Xhosa population","volume":"31","author":"Hitzeroth","year":"2007","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0215","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S0893-133X(99)00156-6","article-title":"Manganese superoxide dismutase gene polymorphism and schizophrenia: relation to tardive dyskinesia","volume":"23","author":"Hori","year":"2000","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0220","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1385\/NMM:8:3:375","article-title":"No association between a functional NAD(P)H: quinone oxidoreductase gene polymorphism (Pro187Ser) and tardive dyskinesia","volume":"8","author":"Hori","year":"2006","journal-title":"Neuromolecular Med"},{"issue":"3","key":"10.1016\/j.pnpbp.2012.10.018_bb0225","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/schbul\/sbp006","article-title":"The dopamine hypothesis of schizophrenia: version III \u2014 the final common pathway","volume":"35","author":"Howes","year":"2009","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0230","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1176\/appi.ajp.161.1.160","article-title":"Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia inpatients","volume":"161","author":"Janno","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0235","first-page":"57","article-title":"The possible role of dopamine autoreceptors in neuroleptic atypicality","volume":"6","author":"Javitt","year":"1988","journal-title":"Psychiatr Dev"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0240","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S0140-6736(94)92347-7","article-title":"Oxidative damage in neurodegenerative disease","volume":"344","author":"Jenner","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0245","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/schbul\/19.2.303","article-title":"Tardive dyskinesia","volume":"19","author":"Jeste","year":"1993","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0250","doi-asserted-by":"crossref","first-page":"52S","DOI":"10.1097\/00004714-198808001-00010","article-title":"Tardive dyskinesia: prevalence, incidence, and risk factors","volume":"8","author":"Kane","year":"1988","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0255","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1016\/j.pnpbp.2008.08.013","article-title":"Manganese superoxide dismutase gene Ala\u20139Val polymorphism might be related to the severity of abnormal involuntary movements in Korean schizophrenic patients","volume":"32","author":"Kang","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0260","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/hup.988","article-title":"Association study between glutathione S-transferase GST-M1, GST-T1, and GST-P1 polymorphisms and tardive dyskinesia","volume":"24","author":"Kang","year":"2009","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0265","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/BF01245320","article-title":"An experimental model of tardive dyskinesia","volume":"33","author":"Klawans","year":"1972","journal-title":"J Neural Transm"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0270","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1212\/WNL.32.5.547","article-title":"Estrogen treatment of dyskinetic disorders","volume":"32","author":"Koller","year":"1982","journal-title":"Neurology"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0280","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000067808","article-title":"Association study of the estrogen receptor polymorphisms with tardive dyskinesia in schizophrenia","volume":"46","author":"Lai","year":"2002","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0275","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3109\/15622975.2010.496870","article-title":"Analysis of genetic variations in the human melatonin receptor (MTNR1A, MTNR1B) genes and antipsychotics-induced tardive dyskinesia in schizophrenia","volume":"12","author":"Lai","year":"2011","journal-title":"World J Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0285","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/00005053-199402000-00009","article-title":"Vitamin E in the treatment of tardive dyskinesia: a replication study","volume":"182","author":"Lam","year":"1994","journal-title":"J Nerv Ment Dis"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0290","first-page":"66","article-title":"Pharmacogenetic studies investigating the adverse effects of antipsychotics","volume":"4","author":"Lee","year":"2007","journal-title":"Psychiatry Invest"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0295","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/B978-0-12-381328-2.00010-9","article-title":"Genetics of tardive dyskinesia","volume":"98","author":"Lee","year":"2011","journal-title":"Int Rev Neurobiol"},{"issue":"1","key":"10.1016\/j.pnpbp.2012.10.018_bb0300","doi-asserted-by":"crossref","first-page":"85","DOI":"10.31887\/DCNS.2006.8.1\/blerer","article-title":"Pharmacogenetics of antipsychotic therapy: pivotal research issues and the prospects for clinical implementation","volume":"8","author":"Lerer","year":"2006","journal-title":"Dialogues Clin Neurosci"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0305","doi-asserted-by":"crossref","first-page":"e04","DOI":"10.4088\/JCP.0207e04","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety and cost outcomes of CATIE and other trials","volume":"68","author":"Lieberman","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0310","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0165-1781(88)90083-2","article-title":"High-dose naloxone in tardive dyskinesia","volume":"26","author":"Lindenmayer","year":"1988","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0315","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/01.fpc.0000184958.05775.66","article-title":"Haplotype analysis of endothelial nitric oxide synthase (NOS3) genetic variants and tardive dyskinesia in patients with schizophrenia","volume":"16","author":"Liou","year":"2006","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0320","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/archpsyc.1991.01810360061009","article-title":"Oxygen radicals and neuropsychiatric illness. Some speculations","volume":"48","author":"Lohr","year":"1991","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0335","first-page":"167","article-title":"A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia","volume":"57","author":"Lohr","year":"1996","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0325","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0140-6736(87)92878-9","article-title":"Alpha-tocopherol in tardive dyskinesia","volume":"1","author":"Lohr","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0330","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/schbul\/14.2.291","article-title":"Vitamin E in the treatment of tardive dyskinesia: the possible involvement of free radical mechanisms","volume":"14","author":"Lohr","year":"1988","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0340","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/0006-3223(90)90490-S","article-title":"Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia","volume":"28","author":"Lohr","year":"1990","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0345","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2165\/00023210-200317010-00004","article-title":"Oxidative mechanisms and tardive dyskinesia","volume":"17","author":"Lohr","year":"2003","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0350","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0014-2999(88)90611-5","article-title":"Behavioural effects of dopamine D-1 and D-2 receptor agonists in monkeys previously treated with haloperidol","volume":"153","author":"Lublin","year":"1988","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0355","first-page":"15","article-title":"Pyrosequencing applications","volume":"373","author":"Marsh","year":"2007","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0360","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.psychres.2004.03.011","article-title":"Polymorphisms of dopamine degradation enzyme (COMT and MAO) genes and tardive dyskinesia in patients with schizophrenia","volume":"127","author":"Matsumoto","year":"2004","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0365","first-page":"47","article-title":"An overview of the mechanism of action of clozapine","volume":"55","author":"Meltzer","year":"1994","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0370","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.tips.2005.05.002","article-title":"The \u2018magic\u2019 of l-DOPA: why is it the gold standard Parkinson's disease therapy?","volume":"26","author":"Mercuri","year":"2005","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0375","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1034\/j.1600-0447.2001.00401.x","article-title":"Familial occurrence of tardive dyskinesia","volume":"104","author":"Muller","year":"2001","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0380","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1345\/aph.1C460","article-title":"Melatonin for the treatment of tardive dyskinesia","volume":"37","author":"Nelson","year":"2003","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0385","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/0278-5846(88)90025-5","article-title":"Treatment of tardive dyskinesia with ceruletide","volume":"12","author":"Nishikawa","year":"1988","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0390","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1517\/14656566.7.2.119","article-title":"Pharmacogenetics for off-patent antipsychotics: reframing the risk for tardive dyskinesia and access to essential medicines","volume":"7","author":"Ozdemir","year":"2006","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0400","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/00041444-200409000-00005","article-title":"Glutathione S-transferase M1 polymorphism may contribute to schizophrenia in the Korean population","volume":"14","author":"Pae","year":"2004","journal-title":"Psychiatr Genet"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0405","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1017\/S1461145704004419","article-title":"Quinone oxidoreductase (NQO1) gene polymorphism (609C\/T) may be associated with tardive dyskinesia, but not with the development of schizophrenia","volume":"7","author":"Pae","year":"2004","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0395","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.psychres.2006.04.011","article-title":"Manganese superoxide dismutase (MnSOD: Ala\u20139Val) gene polymorphism may not be associated with schizophrenia and tardive dyskinesia","volume":"153","author":"Pae","year":"2007","journal-title":"Psychiatry Res"},{"issue":"Pt 1","key":"10.1016\/j.pnpbp.2012.10.018_bb0410","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1042\/bj3000271","article-title":"Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism","volume":"300","author":"Pemble","year":"1994","journal-title":"Biochem J"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0415","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.tig.2006.04.010","article-title":"Epigenetics and twins: three variations on the theme","volume":"22","author":"Petronis","year":"2006","journal-title":"Trends Genet"},{"issue":"20","key":"10.1016\/j.pnpbp.2012.10.018_bb0420","doi-asserted-by":"crossref","first-page":"8236","DOI":"10.1523\/JNEUROSCI.18-20-08236.1998","article-title":"Induction of NF-kappaB activity during haloperidol-induced oxidative toxicity in clonal hippocampal cells: suppression of NF-kappaB and neuroprotection by antioxidants","volume":"18","author":"Post","year":"1998","journal-title":"J Neurosci"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0425","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/1028415021000033767","article-title":"Role of oxidative stress and antioxidants in neurodegenerative diseases","volume":"5","author":"Rao","year":"2002","journal-title":"Nutr Neurosci"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0430","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/1531-8257(200003)15:2<352::AID-MDS1030>3.0.CO;2-X","article-title":"Botulinum toxin for the treatment of oro-facial\u2013lingual\u2013masticatory tardive dyskinesia","volume":"15","author":"Rapaport","year":"2000","journal-title":"Mov Disord"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0435","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1023\/A:1005427323835","article-title":"The role of manganese superoxide dismutase in health and disease","volume":"21","author":"Robinson","year":"1998","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0445","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1080\/j.1440-1614.2000.00737.x","article-title":"The current status of tardive dyskinesia","volume":"34","author":"Sachdev","year":"2000","journal-title":"Aust N Z J Psychiatry"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0440","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/S0006-3223(99)00091-8","article-title":"The preventative role of antioxidants (selegiline and vitamin E) in a rat model of tardive dyskinesia","volume":"46","author":"Sachdev","year":"1999","journal-title":"Biol Psychiatry"},{"issue":"3","key":"10.1016\/j.pnpbp.2012.10.018_bb0450","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1046\/j.1471-4159.1998.71031002.x","article-title":"Induction of reactive oxygen species in neurons by haloperidol","volume":"71","author":"Sagara","year":"1998","journal-title":"J Neurochem"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0455","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3109\/00207458808985767","article-title":"l-tryptophan in neuroleptic-induced tardive dyskinesia","volume":"42","author":"Sandyk","year":"1988","journal-title":"Int J Neurosci"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0460","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1097\/00004714-198808001-00002","article-title":"Tardive dyskinesia, dopamine receptors, and neuroleptic damage to cell membranes","volume":"8","author":"Seeman","year":"1988","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0480","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/sj.mp.4000960","article-title":"Age and the relationship of dopamine D3, serotonin 2C and serotonin 2A receptor genes to abnormal involuntary movements in chronic schizophrenia","volume":"7","author":"Segman","year":"2002","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0470","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s002130000521","article-title":"Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility","volume":"152","author":"Segman","year":"2000","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0465","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/sj.mp.4000842","article-title":"Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia","volume":"6","author":"Segman","year":"2001","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0475","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0006-3223(01)01302-6","article-title":"Interactive effect of cytochrome P450 17\u03b1-hydroxylase and dopamine D3 receptor gene polymorphisms on abnormal involuntary movements in chronic schizophrenia","volume":"51","author":"Segman","year":"2002","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0485","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/carcin\/11.1.33","article-title":"Isoenzyme(s) of glutathione transferase (class Mu) as a marker for the susceptibility to lung cancer: a follow up study","volume":"11","author":"Seidegard","year":"1990","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0490","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1001\/archpsyc.58.11.1049","article-title":"Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study","volume":"58","author":"Shamir","year":"2001","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0495","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1006\/bbrc.1996.1394","article-title":"Structural dimorphism in the mitochondrial targeting sequence in the human manganese superoxide dismutase gene. A predictive evidence for conformational change to influence mitochondrial transport and a study of allelic association in Parkinson's disease","volume":"226","author":"Shimoda-Matsubayashi","year":"1996","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0505","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1385\/NMM:5:2:163","article-title":"Genetic association analysis of neuronal nitric oxide synthase gene polymorphism with tardive dyskinesia","volume":"5","author":"Shinkai","year":"2004","journal-title":"Neuromolecular Med"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0500","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.psychres.2004.06.023","article-title":"Genetic association analysis of the glutathione peroxidase (GPX1) gene polymorphism (Pro197Leu) with tardive dyskinesia","volume":"141","author":"Shinkai","year":"2006","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0510","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/0006-8993(92)91058-M","article-title":"Oxidative stress induced by administration of the neuroleptic drug haloperidol is attenuated by higher doses of haloperidol","volume":"595","author":"Shivakumar","year":"1992","journal-title":"Brain Res"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0515","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1176\/ajp.149.3.391","article-title":"Vitamin E in the treatment of tardive dyskinesia: a double-blind placebo-controlled study","volume":"149","author":"Shriqui","year":"1992","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0520","doi-asserted-by":"crossref","first-page":"49S","DOI":"10.1097\/00004714-198808001-00009","article-title":"Double-blind carbidopa\/levodopa and placebo study in tardive dyskinesia","volume":"8","author":"Simpson","year":"1988","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"10.1016\/j.pnpbp.2012.10.018_bb0525","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0025-6196(12)64861-7","article-title":"Free radicals in medicine. I. Chemical nature and biologic reactions","volume":"63","author":"Southorn","year":"1988","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0530","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/archpsyc.1988.01800330059007","article-title":"The effect of neuroleptics and tardive dyskinesia on smooth-pursuit eye movement in chronic schizophrenics","volume":"45","author":"Spohn","year":"1988","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0535","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/sj.mp.4000249","article-title":"Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients","volume":"2","author":"Steen","year":"1997","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0540","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/carcin\/19.3.433","article-title":"Differences in the catalytic efficiencies of allelic variants of glutathione transferase P1-1 towards carcinogenic diol epoxides of polycyclic aromatic hydrocarbons","volume":"19","author":"Sundberg","year":"1998","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0545","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/BF02247127","article-title":"Neuroleptic-induced vacuous chewing movements as an animal model of tardive dyskinesia: a study in three rat strains","volume":"102","author":"Tamminga","year":"1990","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0550","doi-asserted-by":"crossref","first-page":"71S","DOI":"10.1097\/00004714-198808001-00014","article-title":"Malpractice and tardive dyskinesia: a conceptual dilemma","volume":"8","author":"Tancredi","year":"1988","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0555","first-page":"431","article-title":"The pathophysiologic basis of tardive dyskinesia","volume":"12","author":"Tarsy","year":"1977","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0560","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/B978-0-12-381328-2.00009-2","article-title":"Epidemiology and risk factors for (tardive) dyskinesia","volume":"98","author":"Tenback","year":"2011","journal-title":"Int Rev Neurobiol"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0565","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.schres.2006.12.019","article-title":"Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: role of oxidative stress pathway genes","volume":"92","author":"Thelma","year":"2007","journal-title":"Schizophr Res"},{"issue":"3\u20134","key":"10.1016\/j.pnpbp.2012.10.018_bb0570","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0753-3322(03)00043-X","article-title":"The importance of glutathione in human disease","volume":"57","author":"Townsend","year":"2003","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0575","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1176\/ajp.155.9.1207","article-title":"Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia","volume":"155","author":"Tsai","year":"1998","journal-title":"Am J Psychiatry"},{"issue":"6382","key":"10.1016\/j.pnpbp.2012.10.018_bb0580","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/358149a0","article-title":"Multiple dopamine D4 receptor variants in the human population","volume":"358","author":"Van Tol","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0585","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/0024-3205(77)90490-8","article-title":"Effect of chlorpromazine on central nervous system concentrations of manganese, iron, and copper","volume":"20","author":"Weiner","year":"1977","journal-title":"Life Sci"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0590","first-page":"165","article-title":"Familial occurrence of tardive dyskinesia","volume":"42","author":"Weinhold","year":"1981","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0595","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0034-5687(01)00313-9","article-title":"Ageing and the free radical theory","volume":"128","author":"Wickens","year":"2001","journal-title":"Respir Physiol"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0600","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1176\/ajp.138.12.1618","article-title":"Familial tardive dyskinesia","volume":"138","author":"Yassa","year":"1981","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0605","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/schbul\/18.4.701","article-title":"Gender differences in tardive dyskinesia: a critical review of the literature","volume":"18","author":"Yassa","year":"1992","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0610","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.pnpbp.2009.09.020","article-title":"Oxidative stress in tardive dyskinesia: genetic association study and meta-analysis of NADPH quinine oxidoreductase 1 (NQO1) and superoxide dismutase 2 (SOD2, MnSOD) genes","volume":"34","author":"Zai","year":"2010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2012.10.018_bb0615","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00041444-200309000-00010","article-title":"Interaction between polymorphisms of the dopamine D3 receptor and manganese superoxide dismutase genes in susceptibility to tardive dyskinesia","volume":"13","author":"Zhang","year":"2003","journal-title":"Psychiatr Genet"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584612002746?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584612002746?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,30]],"date-time":"2022-01-30T13:39:51Z","timestamp":1643549991000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584612002746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":123,"alternative-id":["S0278584612002746"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2012.10.018","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oxidative stress and tardive dyskinesia: Pharmacogenetic evidence","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2012.10.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}